

תאריך:

רופא/ה נכבד/ה,
רוקח/ת נכבד/ה,

Fluconazole MBI 2mg/ml

חברת אמ.בי.איי פארמה בע"מ מבקשת להודיע על עדכונים בעלון לרופא של התכשיר שבנדון.

התווית התכשיר:

Fluconazole is indicated in the following fungal infections.

Fluconazole is indicated in adults for the treatment of:

- Cryptococcal meningitis (see section 4.4).
- Coccidioidomycosis (see section 4.4).
- Invasive candidiasis.
- Mucosal candidiasis (including oropharyngeal candidiasis, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis).
- Chronic oral atrophic candidiasis (denture sore mouth) if dental hygiene or topical treatment are insufficient.

Fluconazole is indicated in adults for the prophylaxis of:

- Relapse of cryptococcal meningitis in patients with high risk of recurrence.
- Relapse of oropharyngeal or oesophageal candidiasis in patients infected with HIV who are at high risk of experiencing relapse.
- Prophylaxis of candidal infections in patients with prolonged neutropenia (such as patients with haematological malignancies receiving chemotherapy or patients receiving Haematopoietic Stem Cell Transplantation (see section 5.1)).

Fluconazole is indicated in term newborn infants, infants, toddlers, children and adolescents aged from 0 to 17 years old:

Fluconazole is used for the treatment of mucosal candidiasis (oropharyngeal, oesophageal), invasive candidiasis, cryptococcal meningitis and the prophylaxis of candidal infections in immunocompromised patients. Fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal meningitis in children with high risk of reoccurrence (see section 4.4).

Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.

Consideration should be given to official guidance on the appropriate use of antifungals.

מרכיב פעיל: fluconazole 2mg/ml

צורת המתן של התכשיר : Solution for infusion

4.4 Special warnings and precautions for use

...

Dermatological reactions

Patients have rarely developed exfoliative cutaneous reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, during treatment with fluconazole. **Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported.** AIDS patients are more prone to the development of severe cutaneous reactions to many medicinal products. If a rash, which is considered attributable to fluconazole, develops in a patient treated for a superficial fungal infection, further therapy with this medicinal product should be discontinued. If patients with invasive/systemic fungal infections develop rashes, they should be monitored closely and fluconazole discontinued if *bullous* lesions or *erythema* multiforme develop.

...

Candidiasis

Studies have shown an increasing prevalence of infections with *Candida* species other than *C. albicans*. These are often inherently resistant (e.g. *C. krusei* and *C. auris*) or show reduced susceptibility to fluconazole (*C. glabrata*). Such infections may require alternative antifungal therapy secondary to treatment failure. Therefore, prescribers are advised to take into account the prevalence of resistance in various *Candida* species to fluconazole.

4.6 Fertility, pregnancy and lactation

...

Data from several thousand pregnant women treated with a cumulative dose of ≤ 150 mg of fluconazole, administered in the first trimester, show no increase in the overall risk of malformations in the foetus. **In one large observational cohort study, first trimester exposure to oral fluconazole was associated with a small increased risk of musculoskeletal malformations, corresponding to approximately 1 additional case per 1000 women treated with cumulative doses ≤ 450 mg compared with women treated with topical azoles and to approximately 4 additional cases per 1000 women treated with cumulative doses over 450 mg. The adjusted relative risk was 1.29 (95% CI 1.05 to 1.58) for 150 mg oral fluconazole and 1.98 (95% CI 1.23 to 3.17) for doses over 450 mg fluconazole.**

Undesirable effects

Summary of safety profile:

Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported in association with fluconazole treatment.

השינויים המודגשים ברקע צהוב מהווה החמרה.
בעלון נעשו שינויים נוספים שאינם מהווים החמרה.

העלון מפורסם במאגר התרופות שבאתר משרד הבריאות: <https://data.health.gov.il/drugs/index.html#!/byDrug>
לחילופין, ניתן לקבלו מודפס באמצעות פניה לבעל הרישום, חברת אמ.בי.איי פארמה, ת.ד. 5061, קדימה
טל. 09-7719003

בברכה,

מירי חזן
רוקחת ממונה

